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ABSTRACT 
The incidence of thyroid cancer is low, but when it occurs, it is mainly of the papillary histopathological type. 
Although PET/CT has a limited role in the diagnosis, it plays a significant role in the overall post-surgery management 
of  a  patient  with  thyroid  cancer.  This  follow-up  role  is  important,  especially  in  patients  with  elevated  serum 
thyroglobulin, but negative radioiodine whole body scans. There is increasing evidence that PET/CT should be a part of 
routine care in the Tg positive Radioiodine scan negative patient. © 2006 Biomedical Imaging and Intervention Journal. 
All rights reserved. 
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INTRODUCTION 
Thyroid  cancer  is  an  uncommon  disease,  with  a 
yearly incidence of about 40 out of 100,000 in women 
and 15 out of 100,000 in men. The majority of thyroid 
cancers are of the differentiated type, mainly papillary, 
and  to  a  lesser  extent  follicular  cancer.  For  early 
diagnosis of thyroid cancer, Ultrasonography and fine-
needle aspiration biopsy of thyroid nodules is important. 
Scanning with Tc-99m pertechnetate, Tc-99m sestamibi 
or tetrofosmin and Thallium-201 Chloride, may help in 
some cases [1]. The use of 18 F- fluorodeoxyglucose to 
assess  thyroid  nodules  is  still  under  consideration  [2]. 
Choi  et  al  [3]  found  focal  thyroid  lesion  in  4%  of 
PET/CT  scans,  with  maximum  SUV  of  malignant 
thyroid  lesions  to  be  significantly  higher  than  that  of 
benign lesions. The cancer risk of focal thyroid lesions 
was found to be 39%.  
Age,  sex,  tumour  stage,  and  histopathological 
grading  have  prognostic  significance.  Total 
thyrodectomy is the treatment of choice for differentiated 
thyroid cancer, and the procedure includes lymph-node 
dissection  of  the  central  compartment.  Radioiodine 
treatment  usually  follows  thyroidectomy,  to  ablate 
benign  thyroid  remnants  and  destroy  remaining 
malignant  cells.  Follow-up  with  serum  thyroglobulin 
levels,  sonography  of  the  thyroid  bed,  and  radioiodine 
scintigraphy  is  essential,  especially  to  detect  local 
recurrence  or  distant  metastases  [4].  There  is  good 
correlation  between  the  Tg  levels  (in  the  absence  of 
thyroglobulin autoantibody) and persistence of disease. 
In most cases, undetectable Tg levels suggest absence of 
either  thyroid  tissue  or  distant  metastases  [4,5].  An 
elevated  serum  Tg  suggests  disease  and  is  usually 
associated  with  an  abnormal  I-131  WBS,  with  either 
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local  recurrence  or  distant  metastases.  However, 
discordant  results  between  I-131  WBS  and  serum 
thyroglobulin  have  been  encountered.  In  particular, 
approximately 15 to 20% of patients with high serum Tg 
have negative I-131 diagnostic WBS [5,6]. These false-
negative  scans  may  be  due  to  the  low  dose  of  iodine 
administered  (diagnostic  dose),  presence  of  tumour 
deposits too small to be detected by a gamma camera, or 
loss  of  iodine  concentration  as  a  result  of  tumour 
dedifferentiation,  with  impaired  sodium-iodide 
symporter  (NIS)  system  or  impaired  TSH  receptor 
stimulation.  Several  recent  studies  have  shown  that 
fluorine-18-fluorodeoxyglucose (FDG) positron emission 
tomography (PET) can be used to detect local recurrence 
and distant metastases of thyroid carcinoma, especially 
in those patients who present with high serum Tg, but 
negative I-131 WBS [6-8]. 
SERUM THYROGLOBULIN (TG) AND RADIONUCLIDE 
SCANS IN THE FOLLOW UP OF DIFFERENTIATED 
THYROID CANCER (DTC) 
The follow-up of patients treated for DTC usually 
includes  clinical  monitoring,  serum  thyroglobulin 
measurements,  radionuclide  imaging,  and  anatomic 
imaging (ultrasonography and CT scans) when indicated. 
Both Tg measurements and radionuclide imaging rely on 
TSH  stimulation  for  higher  sensitivity.  The  serum  Tg 
under TSH stimulation (after stopping thyroid hormone 
for  four  to  six  weeks  or  after  two  intramuscular 
injections  of  recombinant  TSH  (rhTSH))  is  a  good 
indicator of persistent or recurrent disease [8]. The Tg 
level is reliable only if Tg antibodies are undetectable 
and recovery of Tg is in the normal range. If high-risk 
and low-risk groups are differentiated, the consensus is 
that  for  low-risk  group  in  complete  remission, 
ultrasonography  of  the  neck  and  rhTSH  stimulated  Tg 
are sufficient for further follow-up [9]. 
For  high-risk  patients,  many  centres  perform 
radioiodine I-131 scans, with Tg under TSH stimulation. 
The specificity of I-131 whole body scans (WBS) is high, 
but  the  sensitivity  is  low  [10].  Radioiodine  therapy 
necessitated by rising Tg levels has a therapeutic effect, 
and  the  post-therapy  WBS  has  a  higher  sensitivity 
compared with a low-dose diagnostic scan [11]. In some 
patients, there is elevation of TSH-stimulated Tg, but the 
diagnostic I-131 WBS is negative. Explanations for false 
negative  WBS  could  be  iodine  contamination, 
insufficient  TSH  stimulation,  small  tumour  volume,  or 
iodine negative metastases [12]. FDG PET/CT should be 
considered if the last two reasons are likely. Other tracers, 
such  as,  Technetium-99m  sestamibi  may  be  used  for 
WBS, especially for soft tissue/nodal disease [13]. 
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PET/CT IN THE FOLLOW UP OF THYROID CANCER 
Using FDG-PET imaging Feine et al. [14] noted that 
differentiated  tumours  with  iodine  avidity  have  low 
glucose metabolism in most patients, with the converse 
also being true, indicating that high glucose metabolism 
signifies poor tumour differentiation and higher possible 
malignant potential. The diagnostic sensitivity of FDG-
PET and I-31 WBS combined was found to be 95%. I-
131  negative,  but  FDG-positive  or  I-131  positive  and 
FDG negative scan  was found in 90% of the patients. 
Examples of this ‘flip-flop’ phenomenon are shown in 
Figure 1 and Figure 2. 
FDG-PET  has  been  advocated  as  a  monitoring 
procedure for patients with:  
1.  High-risk disease 
2.  Adverse histology (e.g., columnar cell, tall cell, 
and insular variants) 
3.  Rising  Tg  levels  with  no  known  anatomic 
source 
4.  Hurthle cell carcinoma 
FDG-PET  has  also  been  recommended  for  post-
treatment  response  assessment,  lesion  dosimetry,  and 
evaluation of the thyroid nodule, but not recommended 
for determining extent of disease in low-risk cases. 
FDG-PET  scans  are  most  useful  in  ‘high-risk’ 
patients,  wherein  tumours  are  more  biologically 
aggressive, and for metastatic disease. Apart from aiding 
in diagnosis, PET measurement of glucose metabolism 
provides  biologic  information,  as  noted  in  the 
standardised uptake value (SUV). Patients whose cancers 
take up FDG well are not likely to respond to radioactive 
iodine.  Furthermore,  the  PET-FDG  SUV  is  a  strong 
predictor  of  adverse  prognosis,  with  higher  SUV’s 
indicating worse overall prognosis [15]. 
The usefulness of FDG-PET may depend on factors, 
such as, Tg level, TSH stimulation by thyroid hormone 
withdrawal,  and  TSH  stimulation  by  rhTSH 
administration. In a study by Schluter et al [16], positive 
FDG-PET scan results were achieved in 11% of patients 
with Tg levels of 10ng/ml or less; this increased to 50% 
among patients with Tg levels between 10 to 20 ng/ml 
and to 93% at Tg levels above 100ng/ml. 
Patients  should  generally  stop  thyroid  hormone 
treatment prior to PET scanning. TSH stimulation could 
be  either  via  hormone  withdrawal  or  by  injection  of 
rhTSH. In a study by Petrich et al [17], the sensitivity of 
FGD-PET was 53% during TSH suppression and 87% 
following rhTSH stimulation. Their conclusion was that 
rhTSH  FDG-PET  suggested  specific  therapeutic 
interventions in 57% of patients, with surgery indicated 
in 23%. 
With the introduction of PET/CT imaging for cancer, 
questions  arise  as  to  whether  PET/CT  imaging  is 
superior  to  PET  and  CT  alone,  and  does  PET/CT 
improve  patient  management  compared  with  both 
modalities  alone.  PET  can  be  considered  functional 
(metabolism),  while  CT  mainly  reflects  anatomy.  In 
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combined PET/CT the CT data are used for attenuation 
correction  and  anatomic  localisation.  There  is  no 
consensus  yet  on  whether  the  CT  should  be  done  as 
contrast-enhanced diagnostic CT or as low-dose CT for 
anatomic  correlation.  Generally  the  PET/CT  scans  are 
done without contrast, as the SUV values are altered by 
contrast,  which  also  reduces  I-131  uptake  when  the 
treatment dose is given. Early clinical results of PET/CT 
fusion  imaging  indicate  that  the  exact  localisation  of 
hypermetabolic  lesions  leads  to  better  reliability  of 
results and higher diagnostic confidence, compared with 
each  imaging  modality  alone  [18,19].  In  general,  for 
staging  and  restaging  of  various  tumours,  there  is 
additional  information  in  about  45%  of  patients  and 
change in management in 15% of patients using PET/CT 
fusion imaging [20]. Furthermore, pitfalls of PET, such 
as,  normal  structures  in  head  and  neck  region,  bowel 
activity, muscle activity, renal excretion, ureteric activity, 
and brown fat tissue could be reduced by using PET/CT 
[20]. 
In our study of thyroid cancer patients with elevated 
Tg, but negative I-131 WBS, lesions were found in 15 
out of 17 patients consistent with metastases, resulting in 
88% sensitivity [21]. Nahas et al [22] report a PET/CT 
sensitivity of 66% in identifying recurrent disease, with a 
specificity  of  100%  and  a  positive  predictive  value  of 
100%.  These  authors  conclude  that  PET/CT  is  most 
useful in the detection and the management of recurrent 
papillary thyroid carcinoma in patients with average Tg 
levels  greater  than  10ng/ml.  A  more  recent  study  by 
Palmedo  et  al  [23]  using  PET/CT  in  patients  with 
suspected  iodine-negative  differentiated  thyroid 
carcinoma,  showed  diagnostic  accuracy  of  93%  for 
PET/CT and 78% for PET alone. They also noted that in 
tumour  positive  PET  patients,  the  PET/CT  fusion 
imaging led to a change of therapy in 48% of the patients. 
The  Centres  for  Medicare  and  Medicaid  Services 
(USA)  began  coverage  of  FDG-PET  procedure  in 
October  2003,  for  restaging  of  recurrent  or  residual 
thyroid cancer of follicular cell origin that has previously 
been treated by thyroidectomy and radioiodine ablation 
in patients with serum Tg levels of 10ng/ml or greater 
and negative I-131 WBS. 
Early this year, the American Thyroid Association 
produced an excellent set of Management Guidelines for 
patients with thyroid nodules and differentiated thyroid 
cancer (24). They recommended that if an empiric dose 
(100  to  200  mCi)  of  radioiodine  fails  to  localise 
persistent  disease,  FDG-PET  should  be  considered, 
especially  in  patients  with  unstimulated  serum 
thyroglobulin levels more than 10 to 20 ng/ml. 
IODINE 124 PET/CT 
Iodine-124 produced in a clinical cyclotron facility 
can be used to identify mediastinal micrometastases in 
thyroid carcinoma [25]. Freudenberg et al [26] reported 
that  Iodine-124  PET/CT  imaging  is  a  promising 
technique  to  improve  treatment  planning  in  thyroid 
cancer. It appears likely that I-124 PET/CT may have an 
important  role  for  individualised  dosimetry  in  patients 
with  metastatic  thyroid  cancer  [27].  Although  I-124  is 
available in only a few hospitals worldwide, it is an ideal 
tracer for dosimetry. The treatment dose with Iodine -131 
can be planned based on the dosimetric studies done with 
PET/CT  using  I-124,  especially  because  the  spatial 
resolution of the PET camera is better than the gamma-
camera  images  using  I-131  (Divgi,  personal 
communication). 
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